Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease

Dry eye disease (DED) is a multifactorial disorder of the ocular surface characterized by symptoms of discomfort, decreased tear quality, and chronic inflammation that affects an estimated 20 million patients in the US alone. DED is associated with localized inflammation of the ocular surface and periocular tissues leading to homing and activation of T cells, cytokine release, and development of hyperosmolar tears. This inflammatory milieu results in symptoms of eye dryness and discomfort. Homing of T cells to the ocular surface is influenced by the binding of lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2), a cell surface adhesion protein, to its cognate ligand, intercellular adhesion molecule-1 (ICAM-1; CD54), which is expressed on inflamed ocular/periocular epithelium and vascular endothelium. LFA-1/ICAM-1 binding within the immunologic synapse enables both T-cell activation and cytokine release. Lifitegrast is a novel T-cell integrin antagonist that is designed to mimic the binding epitope of ICAM-1. It serves as a molecular decoy to block the binding of LFA-1/ICAM-1 and inhibits the downstream inflammatory process. In vitro studies have demonstrated that lifitegrast inhibits T-cell adhesion to ICAM-1-expressing cells and inhibits secretion of pro-inflammatory cytokines including interferon gamma, tumor necrosis factor alpha, macrophage inflammatory protein 1 alpha, interleukin (IL)-1α, IL-1β, IL-2, IL-4, and IL-6, all of which are known to be associated with DED. Lifitegrast has the potential to be the first pharmaceutical product approved in the US indicated for the treatment of both symptoms and signs of DED. Clinical trials involving over 2,500 adult DED patients have demonstrated that topically administered lifitegrast 5.0% ophthalmic solution can rapidly reduce the symptoms of eye dryness and decrease ocular surface staining with an acceptable long-term safety profile. The purpose of this review is to highlight the developmental story – from bench top to bedside – behind the scientific rationale, engineering, and clinical experience of lifitegrast for the treatment of DED.

[1]  Kathryn S. Kennedy,et al.  A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. , 2012, American journal of ophthalmology.

[2]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[3]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[4]  J. Qiao,et al.  Emerging treatment options for meibomian gland dysfunction , 2013, Clinical ophthalmology.

[5]  C. Klee,et al.  Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Thompson,et al.  Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. , 2002, Investigative ophthalmology & visual science.

[7]  Michael E. Stern,et al.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease , 2010, Molecular vision.

[8]  W. Feuer,et al.  Neurostimulation of the Lacrimal Nerve for Enhanced Tear Production , 2015, Ophthalmic plastic and reconstructive surgery.

[9]  Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products , 1998 .

[10]  M. Arkin,et al.  Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. , 2012, ACS medicinal chemistry letters.

[11]  P. Karpecki,et al.  Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. , 2015, Ophthalmology.

[12]  P. Asbell,et al.  Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. , 2009, Transactions of the American Ophthalmological Society.

[13]  J. Kim,et al.  The use of vital dyes in corneal disease. , 2000, Current opinion in ophthalmology.

[14]  J. Gao,et al.  The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. , 1998, Cornea.

[15]  Feisal A Adatia,et al.  Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjögren's syndrome. , 2004, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[16]  S. Bodary,et al.  Competition between intercellular adhesion molecule‐1 and a small‐molecule antagonist for a common binding site on the αl subunit of lymphocyte function‐associated antigen‐1 , 2006, Protein science : a publication of the Protein Society.

[17]  J. Buring,et al.  Prevalence of dry eye syndrome among US women. , 2003, American journal of ophthalmology.

[18]  Ken Paris,et al.  N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. , 2003, Bioorganic & medicinal chemistry letters.

[19]  S. Pflugfelder.  Dry Eye: The Problem , 2004 .

[20]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[21]  G. Mitchell,et al.  Performance and Repeatability of the NEI-VFQ-25 in Patients With Dry Eye , 2002, Cornea.

[22]  R. Dana,et al.  The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials. , 2014, American journal of ophthalmology.

[23]  N. Hogg,et al.  T-cell integrins: more than just sticking points , 2003, Journal of Cell Science.

[24]  Yuki,et al.  Clinical Ophthalmology , 2000, The British journal of ophthalmology.

[25]  Christophe Baudouin,et al.  Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[26]  R. Dana,et al.  Dry eye disease: an immune-mediated ocular surface disorder. , 2012, Archives of ophthalmology.

[27]  S. Joachim,et al.  Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non–Dry Eye Patients , 2015, Cornea.

[28]  N. Hogg,et al.  The role of the integrin LFA‐1 in T‐lymphocyte migration , 2007, Immunological reviews.

[29]  Michael Loran Dustin,et al.  The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. , 1987, Annual review of immunology.

[30]  R. Dana,et al.  Development and validation of a short global dry eye symptom index. , 2007, The ocular surface.

[31]  Programmierbarer Thermoblock,et al.  From industry , 1991 .

[32]  B. Kaluzny,et al.  Tear Meniscus Measurement by Spectral Optical Coherence Tomography , 2012, Optometry and vision science : official publication of the American Academy of Optometry.

[33]  T. Springer,et al.  Purification and structural characterization of LFA-1, a lymphocyte function-associated antigen, and Mac-1, a related macrophage differentiation antigen associated with the type three complement receptor. , 1982, The Journal of biological chemistry.

[34]  T. Gadek,et al.  N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: structure-activity relationship of the benzoyl moiety. , 2004, Bioorganic & medicinal chemistry letters.

[35]  S. Schrader,et al.  Evaluation of Lipid Layer Thickness Measurement of the Tear Film as a Diagnostic Tool for Meibomian Gland Dysfunction , 2013, Cornea.

[36]  L. Presta,et al.  Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. , 2002, Science.

[37]  Kathryn S. Kennedy,et al.  Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. , 2014, Ophthalmology.

[38]  N. Shelke,et al.  Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). , 2010, Investigative ophthalmology & visual science.

[39]  Jason J Nichols,et al.  The Lack of Association Between Signs and Symptoms in Patients With Dry Eye Disease , 2004, Cornea.

[40]  A. Chigaev,et al.  Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion , 2012, Front. Immun..

[41]  R. Dana,et al.  Impact of dry eye syndrome on vision-related quality of life. , 2007, American journal of ophthalmology.

[42]  R. Schiffman,et al.  Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.

[43]  J. Sheppard,et al.  Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[44]  T. Gadek,et al.  Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults. , 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[45]  P. Majmudar,et al.  Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study , 2016, Cornea.

[46]  Martin Grueterich,et al.  The challenge of dry eye diagnosis , 2008, Clinical Ophthalmology.

[47]  Jessica Y. Luo,et al.  ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. , 2004, Experimental eye research.

[48]  C. Murphy,et al.  The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs. , 2011, Investigative ophthalmology & visual science.

[49]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[50]  K. Tsubota,et al.  The international workshop on meibomian gland dysfunction: executive summary. , 2011, Investigative ophthalmology & visual science.

[51]  Wei Yang,et al.  Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. , 2003, Immunity.

[52]  M. Mingari,et al.  Immune response in the conjunctival epithelium of patients with dry eye. , 2010, Experimental eye research.

[53]  William Farley,et al.  Tear cytokine profiles in dysfunctional tear syndrome. , 2009, American journal of ophthalmology.

[54]  Johnny L Gayton,et al.  etiology , prevalence , and treatment of dry eye disease , 2009 .

[55]  J. Groves,et al.  Receptor signaling clusters in the immune synapse. , 2012, Annual review of biophysics.

[56]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[57]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[58]  J. Buring,et al.  Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. , 2009, Archives of ophthalmology.

[59]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.